News Despite Trump price concerns, JP Morgan event anticipates M&... 2017 could be a bumper year for M&A - but Trump's price control threats dominate
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News Sanofi outbids J&J for Actelion merger - reports Reports suggest Sanofi could pay $30 billion for Swiss biotech.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
